Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

— Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. — Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity line Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” […]

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

— Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study — Together, these two studies support the compelling potential ofpelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer — Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in

Siyata Mobile Announces New Order for Private Security Firm

Rising Demand for Private Security Represents a Compelling Market Opportunity Siyata Mobile Inc.(Nasdaq: SYTA)(“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, today announced that its SD7 handsets and VK7 vehicle kits were purchased and deployed by a new customer, Trans-West Security Systems, Inc. (“Trans-West”). https://mma.prnewswire.com/media/2425109/SYTA_Logo.jpg

AerCap Holdings N.V. Announces New $500 Million Share Repurchase Program

AerCap Holdings N.V. (“AerCap”) (NYSE: AER) today announced that its Board of Directors has authorized a new $500 million share repurchase program, which will run through March 31, 2025. This program is in addition to the $105 million of capacity remaining under the share repurchase program announced on May 8, 2024, which runs through December

Darden Restaurants Reports Fiscal 2025 First Quarter Results; Declares Quarterly Dividend; And Reiterates Fiscal 2025 Financial Outlook

Darden Restaurants, Inc. (NYSE: DRI) today reported its financial results for the first quarter ended August25, 2024. First Quarter 2025 Financial Highlights, Comparisons Versus Same Fiscal Quarter Last Year — Total sales increased 1.0% to $2.8 billion, driven by sales from 42 net new restaurants, partially offset by a blended same-restaurant sales* decrease of (1.1)%

HCI Equity Partners Adds Whit Rudder to Investment Team

HCI Equity Partners (“HCI”), a leading lower middle-market private equity firm, today announced that Whit Rudder has joined the firm as an Associate to help evaluate, analyze and monitor investments made by the firm. We’re delighted to welcome Whit to the firm where he will support our deal team,” said Doug McCormick, Managing Partner at

Cobra Acquisitions LLC Announces Approval of Settlement Agreement by Title III Court

PREPA Required to Pay Cobra $150 Million within Ten Business Days Cobra Acquisitions LLC (“Cobra”), a wholly owned subsidiary of Mammoth Energy Services, Inc. (“Mammoth” or the “Company”) (NASDAQ: TUSK), today announced that the previously disclosed Settlement Agreement with the Puerto Rico Electric Power Authority (“PREPA”) was approved by the Title III Court at the

McDermott and BW Offshore Announce Collaboration to Enable Offshore Blue Ammonia Production

McDermott and BW Offshore have entered into a collaboration to advance the technical and commercial viability of offshore blue ammonia production. This strategic partnership aims to enable a viable pathway for offshore blue ammonia production, contributing to the global transition to low-carbon energy sources, and reinforcing both companies’ commitment to sustainable energy practices. The collaboration

Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy secondary to macular degeneration, today announced presentations at the 24th Euretina congress taking place on September 19th-22nd in Barcelona, Spain. https://mma.prnewswire.com/media/1333752/Nanoscope_Therapeutics_Logo.jpg Details for the presentations are as follows: Title:Longitudinal AUC analysis of BCVA in patients treated with

Scroll to Top